About Tempero Bio
Tempero Bio is a company based in Oakland (United States) founded in 2020 by Ricardo Dolmetsch. Tempero Bio has raised $70 million across 1 funding round from investors including Khosla Ventures, 8VC and Aditum Bio. Tempero Bio offers products and services including TMP-301. Tempero Bio operates in a competitive market with competitors including IgGenix, Mithradote Bio, Globin Solutions, metaLead Therapeutics and Sobrera, among others.
- Headquarter Oakland, United States
- Founders Ricardo Dolmetsch
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$70 M (USD)
in 1 rounds
-
Latest Funding Round
$70 M (USD), Series B
Mar 24, 2025
-
Investors
Khosla Ventures
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Tempero Bio
Tempero Bio offers a comprehensive portfolio of products and services, including TMP-301.
Drug for treating substance use disorders like CUD and AUD
Funding Insights of Tempero Bio
Tempero Bio has successfully raised a total of $70M through 1 strategic funding round. The most recent funding activity was a Series B round of $70 million completed in March 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Tempero Bio
Tempero Bio has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Khosla Ventures, 8VC and Aditum Bio.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in technology, life sciences, and related sectors.
|
Locked | Locked | Locked | |
|
Early-stage startups are funded by this venture capital firm.
|
Locked | Locked | Locked | |
|
Serves as a CRO specializing in Phase II clinical trials.
|
Locked | Locked | Locked |
Investor details for Tempero Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Tempero Bio
Investment portfolio details for Tempero Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Tempero Bio
Detailed financials for Tempero Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Tempero Bio Comparisons
Peer comparison for Tempero Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Tempero Bio
Tempero Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as IgGenix, Mithradote Bio, Globin Solutions, metaLead Therapeutics and Sobrera, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutic solutions for food allergies are developed via antibody platforms.
|
|
| Locked | Locked | Locked |
Medication is provided to prevent drug-facilitated sexual assault.
|
|
| Locked | Locked | Locked |
Antidotal therapies for human poisonings are developed using neuroglobin technology.
|
|
| Locked | Locked | Locked |
Next-generation medications against metal poisoning are developed.
|
|
| Locked | Locked | Locked |
Drugs for alcohol use disorders are developed by Sobrera.
|
|
| Locked | Locked | Locked |
Develops innovative technologies for nicotine addiction treatment.
|
Detailed competitors of Tempero Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Tempero Bio
Complete news archive for Tempero Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tempero Bio
Tempero Bio was founded in 2020 and raised its 1st funding round 5 years after it was founded.
Tempero Bio is headquartered in Oakland, United States. It is registered at Oakland, California, United States.
Tempero Bio is a funded company, having raised a total of $70M across 1 funding round to date.
Tempero Bio was founded in 2020 and is based in Oakland, United States, within the biotechnology sector focused on substance use disorders. Treatments for opioid use disorders and related conditions are developed by the company. The lead candidate, TMP-301, is investigated as an orally available metabotropic glutamate receptor 5 negative allosteric modulator for cocaine use disorder and alcohol use disorder. Operations center on advancing these therapeutics through clinical investigation.
Tempero Bio's top competitors include IgGenix, Mithradote Bio and Globin Solutions.
Tempero Bio offers TMP-301.
Tempero Bio has 3 investors. Key investors include Khosla Ventures, 8VC, and Aditum Bio.